Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Drug delivery

Subclass of:

623 - Prosthesis (i.e., artificial body members), parts thereof, or aids and accessories therefor

623100100 - ARTERIAL PROSTHESIS (I.E., BLOOD VESSEL)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
623100430 Antithrombogenic 22
Entries
DocumentTitleDate
20090259301Detector for abnormal conditions inside body - An implant capable of sensing pressure, force, pH level or any other condition releases a chemical into the body when a pre-set limit is exceeded. The chemical is chosen to be detectable by the person without the need of any external equipment. Typical chemicals are dyes causing coloration visible to the person or chemicals causing a mild and clearly identified reaction such as odor, taste, or unique sensation. The released chemical can have therapeutic effects as well. The invention is particularly suitable for detection of abnormal increase of internal pressure in order to monitor stent grafts.10-15-2009
20090198321Drug-Coated Medical Devices for Differential Drug Release - The embodiments described herein relate generally to medical devices that are useful for delivering one or more therapeutic agents to a body tissue of a subject, and methods for making and using such devices. In particular, the embodiments relate to a medical device such as a stent having a sidewall structure comprising a plurality of struts, in which one or more therapeutic agents are released from different surfaces of the struts at different release profiles. More particularly, the embodiments relate to a stent having a sidewall structure comprising a plurality of struts, in which the two side surfaces of each strut are coated with a coating composition that is different from the coating composition used to coat the outer surface and/or inner surface of the strut.08-06-2009
20090012604POLYMERIC, DEGRADABLE DRUG-ELUTING STENTS AND COATINGS - Absorbable stents and absorbable stent coatings have been developed with improved properties. These devices preferably comprise biocompatible copolymers or homopolymers of 4-hydroxybutyrate, and optionally poly-L-lactic acid and other absorbable polymers and additives. Compositions of these materials can be used to make absorbable stents that provide advantageous radial strengths, resistance to recoil and creep, can be plastically expanded on a balloon catheter, and can be deployed rapidly in vivo. Stent coatings derived from these materials provide biocompatible, uniform coatings that are ductile, and can be expanded without the coating cracking and/or delaminating and can be used as a coating matrix for drug incorporation.01-08-2009
20110190876DEVICE FOR LOCAL AND/OR REGIONAL DELIVERY EMPLOYING LIQUID FORMULATIONS OF THERAPEUTIC AGENTS - Medical devices may be utilized for local and regional therapeutic agent delivery. These therapeutic agents or compounds may reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including restenosis, vulnerable plaque, and atherosclerosis in type 2 diabetic patients. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned.08-04-2011
20090192593Stent for Delivery a Therapeutic Agent from a Side Surface of a Stent StSrut - Described herein are implantable medical devices, such as implantable or intravascular stents, for delivering a therapeutic agent, and methods for making such medical devices. In one embodiment, the medical device comprises a stent having a plurality of struts, at least one of which has a cavity disposed therein. A therapeutic agent is delivered from the cavity through and opening in a strut surface. In another embodiment, the medical device is a stent having a coating disposed on the side surface(s) of at least one strut for deliver of a therapeutic agent from the coating.07-30-2009
20110196479COATED IMPLANTABLE MEDICAL DEVICE - A coated implantable medical device includes a structure adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer posited on one surface of the structure; and at least one layer of a bioactive material posited on at least a portion of the coating layer. Preferably the structure is a stent graft.08-11-2011
20110202125ARTIFICIAL STENT AND ITS PREPARATION METHOD - An artificial stent and its preparation method. The artificial stent comprises a stent body and a coating on it. The artificial stent is characterized in that the coating comprises a drug-loaded layer containing silk fibroin and a drug. The drug-loaded layer has a microporous structure substantially consists of silk fibroin and loaded with the drug. The microporous structure is obtained by a method comprising: uniformly coating the surface of the stent body with a solution of silk fibroin, denaturing by heat or chemical reagents; soaking the stent with purified water; then freeze drying and warming-drying, so as to from a microporous structure of the coating; loading the drug into the micropores in the coating; and removing the stent and drying. Silk fibroin used to coat the stent is a natural bio-material with great bio-compatibility; an can be absorbed and metabolized slowly by human body without adverse side effects, overcoming certain adverse effects of conventional drug-coated stents.08-18-2011
20090177272SELF-EXPANDING DEVICES AND METHODS THEREFOR - Described here are self-expanding devices and methods of using and making them. The devices may be useful in a variety of locations within the body, for a number of different uses. In some variations, the devices have a first compressed configuration enabling low profile delivery through a delivery device, a second expanded configuration for apposition against tissue, and comprise either a single continuous filament or at least two non-intersecting filaments. In some variations, the device is formed into a shape having a series of peaks and valleys. At least one of the peaks and valleys may have a loop at then end thereof. At least a portion of these devices may be capable of biodegrading over a predetermined period of time, and the devices may be configured for drug delivery. Methods of treating one or more sinus cavities are also described here.07-09-2009
20090157171Treatment indications informed by a priori implant information - Systems and methods are described for implementing or deploying therapeutic administration systems for obtaining a priori implant information and signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants; or obtaining a flow-change-indicative measurement and signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement; or obtaining one or more indications of a lactic material in a vicinity of one or more body lumens and accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens; or one or more capture components configured to accelerate a decrease in a local concentration of one or more therapeutic structures along a downstream portion of a vasculature and one or more dispensation components configured to release the one or more therapeutic structures into an upstream portion of the vasculature.06-18-2009
20100106243Implant Made of Biocorrodible Iron or Magnesium Alloy - The invention relates to an implant made of a biocorrodable metallic material and having a coating composed of or containing a biocorrodable polyphosphate, polyphosphonate, or polyphosphite.04-29-2010
20100106242STENT AND METHOD FOR MAKING A STENT - A stent includes a body, a layer of therapeutic agent over at least a section of the body, and a sealant layer over the layer of therapeutic agent. The sealant layer includes a through hole that allows release of the therapeutic agent of the therapeutic agent layer through the through hole when the stent is deployed in a blood vessel.04-29-2010
201001062443-Deazaadenosine prevents atherosclerosis and graft vasculopathy - A stent is coated with 3-deazaadenosine or an analog of 3-deazaadenosine for the prevention and/or treatment of vascular disease or graft rejection.04-29-2010
20100331968Zeolites for Delivery of Nitric Oxide - There is described zeolites containing releasably adsorbed nitric oxide, methods of preparing the zeolites, methods of releasing the nitric oxide into a solution or into air and uses of the zeolites in therapy.12-30-2010
20100094408Drug-Delivery Endovascular Stent and Method for Treating Restenosis - An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of the macrocyclic triene immunosuppressive compound everolimus. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns.04-15-2010
20090043378Biocompatible Polymer System for Extended Drug Release - A self-orienting biocompatible polymer system incorporating a hydrophilic surface and a hydrophobic core are disclosed. The hydrophilic surface aids in biocompatibility while the hydrophobic core allows the polymer system to accommodate a hydrophobic drug. Medical devices coated with the polymer system are also disclosed.02-12-2009
20110009953RAPAMYCIN RESERVOIR ELUTING STENT - Implantable medical devices may be utilized to locally delivery one or more drugs or therapeutic agents to treat a wide variety of conditions, including the treatment of the biological organism's reaction to the introduction of the implantable medical device. These therapeutic agents may be released under controlled and directional conditions from a stent so that the one or more therapeutic agents reach the correct target area, for example, the surrounding tissue.01-13-2011
20110015724MEDICAL DEVICE HAVING HYDROPHILIC COATINGS - The present invention relates to a medical device having a coating comprising at least one polyurethane urea, wherein the coating comprises at least one polyurethane urea terminated with a copolymer unit of polyethyloxide and polypropyloxide.01-20-2011
20130060327BIODEGRADABLE SELF-EXPANDING PROSTHESIS - Disclosed herein is a biodegradable prosthesis that includes a first end, a second end, and an elongate tubular body with a lumen therethrough. The prosthesis can have a first layer comprising a set of flexible interbraided bioabsorbable filaments, and optionally a set of flexible interbraided metallic filaments. Also, the prosthesis can have a second layer comprising a porous thermoplastic material that can be either an outer layer or an inner layer relative to the first layer. The prosthesis can include other features including branch apertures, folded portions, and attachment mechanisms for the first and second layers.03-07-2013
20090054971DRUG ELUTING STENT SYSTEM AND MANUFACTURING PROCESS OF DRUG ELUTING STENT SYSTEM - This invention provides a drug eluting stent system provided with a stent, which carries thereon a biologically/physiologically active substance, and a deoxidant within a package, and a manufacturing process of the drug eluting stent system. The drug eluting stent system has a substantially extended expiration date and permits a practical application.02-26-2009
20090299466Local Delivery of Matrix Metalloproteinase Inhibitors - Disclosed are medical devices and methods for the local delivery and treatment of vascular conditions. The methods and treatments involve local delivery of at least one matrix metalloproteinase inhibitor. The vascular conditions described herein include plaque rupture, aneurysm, stenosis, restenosis, atherosclerosis and combinations thereof.12-03-2009
20090287300EXTRACTION OF SOLVENTS FROM DRUG CONTAINING POLYMER RESERVOIRS - A process for reducing solvent contents in drug-containing polymeric compositions may be utilized to reduce the solvent content in implantable medical device wherein the compositions are in reservoirs. Specifically, the solvent contents in the drug-containing polymeric compositions are first reduced by one or more conventional drying methods, to a range from about 0.5 weight percent to about 10 weight percent of the total weight of the polymeric composition. Subsequently, the drug-containing polymeric compositions are further treated by a low temperature drying method for further reduction of the solvent content.11-19-2009
20110022160Medical Devices Having an Inorganic Coating Layer Formed by Atomic Layer Deposition - Medical devices having a coating that comprises one or more inorganic coating layers. The inorganic coating layer may be formed by a self-limiting deposition process, such as atomic layer deposition. The inorganic coating layer may have a thickness of less than 30 nm. The inorganic coating layer may also be used in combination with a therapeutic agent as a control release barrier. The inorganic coating layer may have various desirable properties, including, for example, resistance to cracking or delamination, high degree of uniformity, high degree of conformality, and/or compatibility with low deposition temperatures.01-27-2011
20090234441METHOD AND APPARATUS FOR PREVENTING DIALYSIS GRAFT INTIMAL HYPERPLASIA - To prevent intimal hyperplasia within a dialysis graft, a flexible tube comprising the dialysis graft is coated interiorly before placement with an anticarcinogen or mitosis-inhibiting agent for preventing cell division. The graft can also be irradiated with light energy by directing light into the lumen of the tube that has been grafted in place, thereby preventing or reducing dialysis graft intimal hyperplasia and reducing inflammation. The light source can be a light emitting diode (LED) or a chemical light source, i.e., a chemiluminescent substance for producing cool light energy within the graft to prevent or reduce the symptoms of GIH. When phototherapy is used, the body is exposed to light radiation at the site of the graft in sufficient amount to prevent undesired cell proliferation within the vessels, the graft, or surrounding tissue where the invention is used without detectable damage to body tissue. For various applications, visible light can be used, e.g., visible blue or red light or the combination is employed. Blue and red light can be produced by an incandescent lamp or other suitable lamp, an LED, a laser or chemical light source with wavelengths predominantly between about 300 nm to about 800 nm.09-17-2009
20090012605Coronary stent that releases medicamentuous composition to prevent and treat restenosis and fabrication process - A stent is described that releases medicamentuous composition to prevent and treat restenosis and the fabrication process that comprehends between 10.0 to 500.0 Ug/cm01-08-2009
20090012603IMPLANTABLE MEDICAL DEVICES HAVING ADJUSTABLE PORE VOLUME AND METHODS FOR MAKING THE SAME - The present invention is directed to implantable medical devices which may be used for controllably releasing a therapeutic agent within a patient and methods for making the same. These medical devices may include porous coatings, which may be polymer-free, located on an outer surface or abluminal surface of the medical device. The medical device may be a stent. The pores of the porous coating may be expandable to facilitate loading of the therapeutic agent. The medical device may be triggerable upon implantation of the medical device such that the volume of the voids shrinks to eject the therapeutic agent. The voids may be slots in the stent. Expandable materials or structures may be positioned in the voids to expand upon implantation and eject the therapeutic agent.01-08-2009
20100049308VESSEL STENT WITH MULTI DRUG-COATINGS - A stent with multi drug-coatings includes a stent body and active drugs. A portion of the surface or the entire surface of the stent body is covered with at least one layer of active drug coating. Use of such a stent not only can accelerate endothelialization of coronary, but also resist cell proliferation, resist the migration of smooth muscle cells, reduce the formation of thrombus and the inflammatory reaction of cells and recover the flexibility of vascular tissues. Multi drug-coatings can prevent the multiple phases of restenosis, resist the release of drugs at different phases of endothelial repair, and play a role in co-resisting vessel stent restenosis by various drugs. Well-composed multi drug-coatings make the coating area and coating layers of drug-eluting stent and drugs compatibility more reasonable, make the use of drug-eluting stent more secure, and produce better treatment effects.02-25-2010
20090093875DRUG ELUTING STENTS WITH PROLONGED LOCAL ELUTION PROFILES WITH HIGH LOCAL CONCENTRATIONS AND LOW SYSTEMIC CONCENTRATIONS - A drug eluting stent can include a stent body having a polymeric coating with a lipophilic and/or hydrophilic element. A drug that has a bioactivity that inhibits cell proliferation can be disposed in the polymeric coating. The drug can be present in the polymer at an amount greater than or equal to about 150 ug/cm04-09-2009
20110282436Endoprosthesis - A stent includes a MOF which adjusts pore size upon desorption or adsorption of organic molecules.11-17-2011
20100114302ENDOVASCULAR DEVICES WITH AXIAL PERTURBATIONS - Endovascular devices are provided. The endovascular devices include a conformable scaffold with one or more outpocketings. The outpocketing in the endovascular device creates a corresponding outpocketing of a vessel wall, thereby altering local fluid dynamics.05-06-2010
20110125254DRUG RELEASING MEMBRANE FOR STENT AND DRUG RELEASING STENT FOR EXPANDING INTRALUMINAL COMPRISING THE SAME - The present invention relates to a drug releasing membrane for stent and a drug releasing stent for intraluminal expansion comprising the same. The drug releasing membrane according to the present invention has a two layer structure consisting of an inner layer M05-26-2011
20090259302COATING COMPRISING POLY (ETHYLENE GLYCOL)-POLY (LACTIDE-GLYCOLIDE-CAPROLACTONE) INTERPENETRATING NETWORK - Methods for fabricating coatings for implantable medical devices are disclosed. The method comprises forming a coating on an implantable device comprising an interpenetrating network or semi-interpenetrating network. The interpenetrating network or semi-interpenetrating network comprises poly(ethylene glycol) and an aliphatic polyester copolymer. It is also provided an implantable device and a method of using the implantable device.10-15-2009
20100241220Peripheral Stents Having Layers - Provided herein is a coated coronary stent, comprising: a. stent; b. a plurality of layers deposited on said stent to form said coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.09-23-2010
20110295365Anti-viral compositions and methods for administration - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, articles of manufacture, systems, and devices. Certain embodiments relate to anti-viral compositions, methods, articles of manufacture, systems and devices.12-01-2011
20090030504Medical devices comprising porous inorganic fibers for the release of therapeutic agents - In accordance with an aspect of the invention, implantable or insertable medical devices are provided which comprise a substrate and a therapeutic-agent-loaded porous inorganic fiber.01-29-2009
20100036482DRUG DELIVERY SYSTEM AND METHOD OF MANUFACTURING THEREOF - A medical device for surgical implantation adapted to serve as a drug delivery system has one or more drug loaded holes with barrier layers to control release or elution of the drug from the holes or to control inward diffusion of fluids into the holes. The barrier layers are non-polymers and are formed from the drug material itself by ion beam processing. The holes may be in patterns to spatially control drug delivery. Flexible options permit combinations of drugs, variable drug dose per hole, multiple drugs per hole, temporal control of drug release sequence and profile. Methods for forming such a drug delivery system are also disclosed.02-11-2010
20100280599CALCIUM PHOSPHATE COATED IMPLANTABLE MEDICAL DEVICES, AND ELECTROCHEMICAL DEPOSITION PROCESSES FOR MAKING SAME - This invention relates to novel calcium phosphate coated implantable medical devices, and electrochemical deposition processes for making same. A process of coating an implantable medical device with a calcium phosphate coating comprising: (a) subjecting a substrate to a surface pretreatment whereby adhesion of the calcium phosphate coating to the substrate is enhanced; (b) immersing the pretreated substrate in an electrolyte comprising calcium and phosphate species; and (c) coating calcium phosphate onto the substrate by electrochemical deposition.11-04-2010
20090149948MEDICAL DEVICES CONTAINING SILICATE AND CARBON PARTICLES - According to one aspect of the present invention, implantable and insertable medical devices are provided which contain one or more particle-containing regions that comprise silicate particles and carbon particles.06-11-2009
20090149947Implantable device for drug delivery and improved visibility - The present invention provides an implantable device as delivery device for at least one therapeutic agent being composed of at least one type of base material comprising at least two types of reservoirs for at least one therapeutic agent whereby each type of reservoir independently provides identical or different release rates for the at least one therapeutic agent.06-11-2009
20100268329Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease - A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.10-21-2010
20100280600DUAL DRUG STENT - Implantable medical devices may be utilized to locally delivery one or more drugs or therapeutic agents to treat a wide variety of conditions, including the treatment of the biological organism's reaction to the introduction of the implantable medical device. These therapeutic agents may be released under controlled and directional conditions so that the one or more therapeutic agents reach the correct target area, for example, the surrounding tissue and/or the bloodstream.11-04-2010
20090138076MEDICAL DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS - The present invention is generally directed to medical devices, and more specifically to medical devices that are at least partially insertable or implantable into the body of a patient. The medical devices generally comprise (a) a therapeutic agent, more typically, a high-molecular-weight therapeutic agent, and (b) at least one polymeric layer, which typically acts to control the release of the therapeutic agent from the medical device. Also disclosed herein are methods of making such medical devices.05-28-2009
20120109284BARE METAL STENT WITH DRUG ELUTING RESERVOIRS HAVING IMPROVED DRUG RETENTION - Implantable medical devices may be utilized to locally delivery one or more drugs or therapeutic agents to treat a wide variety of conditions, including the treatment of the biological organism's reaction to the introduction of the implantable medical device. These therapeutic agents may be released under controlled and directional conditions from a stent having reservoirs so that the one or more therapeutic agents reach the correct target area, for example, the surrounding tissue. Features may be incorporated into the walls and bases of these reservoirs to improve securement of the drug construct.05-03-2012
20100125329Pseudoelastic stents having a drug coating and a method of producing the same - An implantable medical device, such as a stent, having linear pseudoelastic behavior and a polymeric drug coating is disclosed. A method of producing an implantable medical device having linear pseudoelastic behavior and a polymeric drug coating is also disclosed.05-20-2010
20080281408Artificial Blood Vessel - It is an object of the present invention to retain on an artificial blood vessel material an endothelial cell growth-promoting agent, for example the angiogenic factor HGF, without impairing its activity, thereby providing an artificial blood vessel having the function of promoting endothelialization. Such an object can be attained by an artificial blood vessel that includes a porous tubular structure formed from, for example, polytetrafluoroethylene and, layered and immobilized in sequence onto at least the inner surface thereof, (1) a polyamino acid urethane copolymer, (2) collagen or gelatin, and (3) an endothelial cell growth-promoting agent having collagen-binding activity. Preferred examples of the endothelial cell growth-promoting agent include a fusion protein of a polypeptide having collagen-binding activity such as, for example, a fibronectin-derived polypeptide and an angiogenic factor, in particular, HGF.11-13-2008
20110172763Matrix Coated Stent - The present invention relates generally to a drug eluting stent containing metallic surfaces modified in microsphere metallic matrix structure and methods for making same. More specifically, the invention relates to an expandable and implantable vascular stent having at least one matrix layer that promotes improved cellular adhesion properties for healing promotion healing and long term biocompatibility. In the case of coronary stents, the metallic matrix layer promotes re-endothelialization at sites of stent implantation, improves overall healing, and reduces inflammation and intimal disease progression. The microsphere metallic matrix layer may be optionally loaded with one or more therapeutic agent to further improve the function of the implanted stent and further augment clinical efficacy and safety. The active compounds are selected primarily for their anti-proliferative, immunosuppressive, and anti-inflammatory activities, among other properties, which prevent, in part, smooth muscle cell proliferation and promote endothelial cell growth.07-14-2011
20100100171Method Of Manufacturing An Implantable Polymeric Medical Device - A polymeric tube is positioned on a polymeric mandrel and then laser cut to form an implantable medical device, such as a stent. The method reduces contamination of the inner surface of the stent, which would be caused if conventional glass or metal mandrels are used, while simultaneously reducing damage to the inner surface of the stent due to the shielding effect of the polymeric mandrel.04-22-2010
20100137976Systems and Methods for Treating Heart Tissue Via Localized Delivery of Parp Inhibitors - The systems and methods of the present disclosure, in a broad aspect, provide for treatment of cardiac tissue via localized delivery of PARP inhibitors. These systems include a composition comprising at least one poly(ADP-ribose) polymerase (PARP) inhibitor; and at least one delivery device for introducing the composition into the cardiac tissue.06-03-2010
20080249617Triflusal-Containing Polymers for Stent Coating - New triflusal-containing polymeric compounds resulting from the polymerization of 2-(methacryloyloxy)ethyl 2-acetyloxy-4-(trifluoromethyl)benzoate with butyl acrylate are described. These new polymers exhibit good adhesion and crack-bridging properties and are particularly suitable for the coating of stents.10-09-2008
20080275544Medical devices for delivering a therapeutic agent and method of preparation - A method for making an intravascular stent by applying to the body of a stent a solution which includes a solvent, a polymer dissolved in the solvent and a therapeutic substance dispersed in the solvent and then evaporating the solvent. The inclusion of a polymer in intimate contact with a drug on the stent allows the drug to be retained on the stent during expansion of the stent and also controls the administration of drug following implantation. The adhesion of the coating and the rate at which the drug is delivered can be controlled by the selection of an appropriate bioabsorbable or biostable polymer and the ratio of drug to polymer in the solution. By this method, drugs such as dexamethasone can be applied to a stent, retained on a stent during expansion of the stent and elute at a controlled rate.11-06-2008
20080288057Bioactive Stents For Type II Diabetics and Methods for Use Thereof - The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.11-20-2008
20080288058MEDICATED POROUS METAL PROSTHESIS AND A METHOD OF MAKING THE SAME - A porous prosthesis for delivering a medication to the site of implantation, and a method of making the same, is disclosed.11-20-2008
20080215138COATED IMPLANTABLE MEDICAL DEVICE - A coated implantable medical device 09-04-2008
20100145437Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface - The invention is directed to mechanisms and methods that reduce the delamination of a therapeutic agent from a stent. The mechanisms include holes (channels, wells, and other hole configurations), protrusions, sintered metal cores, clamps/staples, pins, and stainless steel shields.06-10-2010
20110208294BIOABSORBABLE MEDICAL DEVICE WITH COATING - A biodegradable, bioabsorbable medical device with a coating for capturing progenitor endothelial cells in vivo and delivering a therapeutic agent at the site of implantation. The coating on the medical device is provided with a biabsorbable polymer composition such as a bioabsorbable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive for controlling the rate of delivery of the therapeutic agent.08-25-2011
20100036480ENDOVASCULAR MAGNETIC METHOD FOR TARGETED DRUG DELIVERY - The method for endovascular magnetic targeting drug delivery in a vascular wall and adjoining tissues, wherein an endovascular mesh stent with paramagnetic properties is preliminary implanted in the area of interest by a catheter, a polymeric magneto-responsive carrying agent in the form of particles, containing a drug, is injected, and a magnetic field is applied, characterized in that, at least, one temporary catheter is introduced in the right atrium, and/or in ventricles of heart, and/or in a coronary sinus and/or in a coronary vein, which distal end takes a position close to the implanted mesh stent, thereupon, a gradient permanent magnetic field is generated and adjusted by means of a permanent magnet and/or a solenoid with the core, connected to an electric power source, which magnet or solenoid are located at the distal end of each temporary catheter, where the maximal gradient of magnetic field is located in the implanted endovascular stent, principally on the stent mesh.02-11-2010
20090138075Bifurcated Stent with Drug Wells for Specific Ostial, Carina, and Side Branch Treatment - The invention is directed to a stent that delivers multiple therapeutic regimens from different regions of the stent.05-28-2009
20090118818ENDOPROSTHESIS WITH COATING - An endoprosthesis such as a coronary stent includes a surface region that defines a depression in the form of a channel, the depression having an interior surface, and an enhanced roughness on the interior surface.05-07-2009
20100004738DRUG DELIVERY COATING FOR USE WITH A MEDICAL DEVICE AND METHODS OF TREATING VASCULAR INJURY - The present inventions provide various embodiments of methods for one or more of treating vascular injury, neointima proliferation and/or local inflammation in a mammal by locally administering therapeutic compound comprising a mTOR targeting compound and a calcineurin inhibitor. In various aspects, the therapeutic compound comprises a bio-absorbable carrier component carrier component at least partially formed of a cellular uptake inhibitor and a cellular uptake enhancer, a mTOR targeting compound and a calcineurin inhibitor. In various aspects, the present invention provides for controlled delivery, which is at least partially characterized by total and relative amounts of a cellular uptake inhibitor and cellular uptake enhancer in a bio-absorbable carrier component.01-07-2010
20090143855Medical Device Including Drug-Loaded Fibers - An endovascular or intraluminal stent comprising an expandable framework including a plurality of interconnected undulating or otherwise connected segments, and a plurality of fibers disposed on the expandable framework. At least a portion of the plurality of fibers is loaded with a therapeutic agent.06-04-2009
20090024210MEDICATION DEPOT FOR MEDICAL IMPLANTS - A method for producing an agent depot for mechanical connection to a surface of an endovascular implantable body, comprising a) providing one or more polymers; b) providing one or more agents; and c) producing an agent depot from said polymers and said agents, the agent depot being mechanically connectable to the surface of the body using force action or adhesive.01-22-2009
20090024209Hypotubes for Intravascular Drug Delivery - An implantable device capable of delivering drugs is disclosed. An example of the device is a stent that comprises at least one hypotube having a lumen and one or more pores. The lumen of the hypotube is configured to retain drugs that can be eluted through the one or more pores after deployment at a treatment site.01-22-2009
20090292352METHODS OF MAKING MEDICAL DEVICES - A method of making a stent includes providing a tubular member having a first layer, the first layer and the tubular member having different compositions, removing a portion of the tubular member, and removing a portion of the first layer from the tubular member.11-26-2009
20090082854Pitted metallic implants and method of manufacturing thereof - A method of fabricating a conductive prosthetic, such as a stent, with a dimpled surface comprising the steps of: (i) providing a blank; (ii) electrochemically eroding superfluous material to leave a structural skeleton, (iii) electropolishing, (iv) dimpling the surface of the structural skeleton by selectively electrochemically eroding recesses on the surface of the prosthetic and (v) impregnating the recesses with a bioactive material, and prosthetics such as stents with dimpled surfaces fabricated thereby.03-26-2009
20090082855COATING FOR CONTROLLED RELEASE OF A THERAPEUTIC AGENT - Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.03-26-2009
20090204204Drug/Drug Deliver Systems For The Prevention And Treatment Of Vascular Disease - A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.08-13-2009
20120078348APPARATUS AND METHODS FOR DELIVERING AT LEAST ONE THERAPEUTIC AGENT - The present invention provides apparatus and methods for treating tissue by delivering at least one therapeutic agent to the tissue. In one embodiment, the apparatus comprises first and second membranes (03-29-2012
20080262606POLYMERS CONTAINING SILOXANE MONOMERS - A polymer of siloxanes as flexibility monomers and strength monomers is provided. It is also provided a polymer blend that contains a polymer formed of siloxane monomers and strength monomers and another biocompatible polymer. The biocompatible polymer or polymer blend described herein and optionally a bioactive agent can form a coating on an implantable device such as a drug-delivery stent. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.10-23-2008
20080234809Stent Graft System With Injection Tube - A stent graft system with injection tube, the stent graft system for injecting an agent into an aneurysmal sac from an external pressurized source, including a stent graft having a permeable graft and a framework supporting the permeable graft; and an injection tube connected to the stent graft adjacent to the permeable graft, the injection tube having a plurality of holes adjacent to the permeable graft. The external pressurized source forces the agent through the plurality of holes into the aneurysmal sac.09-25-2008
20090005859ENDOLUMINAL IMPLANT WITH THERAPEUTIC AND DIAGNOSTIC CAPABILITY - An apparatus includes an endoluminal implant, a RF coupling coil coupled to the endoluminal implant and a therapeutic transducer electrically coupled to the RF coupling coil and physically coupled to the endoluminal implant. The RF coupling coil supplies electrical power to the therapeutic transducer. The therapeutic transducer has a capability for delivering therapeutic energy to a lumen disposed within the endoluminal implant in response to signals coupled via the RF coupling coil.01-01-2009
20090222080MEDICAL STENT PROVIDED WITH INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA - A stent provided with a composition that includes at least one inhibitor of TNF-alpha is disclosed. The stent is useful in treating smooth muscle cell proliferation, such as stenosis and preventing restenosis in vascular ducts.09-03-2009
20090240324Drug Eluting Stent and Method of Making the Same - A drug eluting stent comprising a multilayer tubular structure which includes at least one intermediate layer having reservoirs therein for deposition of a drug, the intermediate layer eluting drug in a lateral direction, and methods of making the same.09-24-2009
20100274353BIOMIMETIC VASCULAR NETWORK AND DEVICES USING THE SAME - The invention provides method of fabricating a scaffold comprising a fluidic network, including the steps of: (a) generating an initial vascular layer for enclosing the chamber and providing fluid to the cells, the initial vascular layer having a network of channels for fluid; (b) translating the initial vascular layer into a model for fluid dynamics analysis; (c) analyzing the initial vascular layer based on desired parameters selected from the group consisting of a characteristic of a specific fluid, an input pressure, an output pressure, an overall flow rate and combinations thereof to determine sheer stress and velocity within the network of channels; (d) measuring the sheer stress and the velocity and comparing the obtained values to predetermined values; (e) determining if either of the shear stress or the velocity are greater than or less than the predetermined values, and (f) optionally modifying the initial vascular layer and repeating steps (b)-(e). The invention also provides compositions comprising a vascular layer for use in tissue lamina as well as a medical devices having a vascular layer and kits.10-28-2010
20100274352Endoprosthesis with Selective Drug Coatings - An endoprosthesis such as a coronary stent includes a luminal surface, at least a portion of which is covered with a first coating including a first drug, and an abluminal surface, at least a portion of which is covered with a second coating including a second drug. The first drug has a first eluting profile based on the first coating, and the second drug has a second eluting profile based on the second coating, the first eluting profile being different from the second eluting profile. Methods of making the same are also provided.10-28-2010
20100179645MEDICAL DEVICES HAVING MULTIPLE LAYERS - Described herein are medical devices which are configured for implantation or insertion into a subject, preferably a mammalian subject. The medical devices contain one or more multilayer regions, which contain: (a) one or more (typically a plurality of) charged nanoparticle layers and (b) one or more (typically a plurality of) charged polyelectroyte layers. Such multilayers have a number of desirable attributes, including high strength, non-compliance, and flexibility. Also described herein are methods of making such devices.07-15-2010
20100161038Medical device for intra-lumenal delivery of pharmaceutical agents - The present invention relates to intra-lumenal drug delivery devices. The device, such as a stent, is coated or impregnated with a pharmaceutical agent suitable for use in treatment of restenosis, pulmonary hypertension, and cancer. Suitable pharmaceutical agents include vasodilators and chemotherapeutics.06-24-2010
20100161039ADHESION PROMOTING TEMPORARY MASK FOR COATED SURFACES - An expandable medical device includes a plurality of elongated struts, forming a substantially cylindrical device which is expandable from a first diameter to a second diameter. A plurality of different beneficial agents may be loaded into different openings within the struts for delivery to the tissue. For treatment of conditions such as restenosis, different agents are loaded into different openings in the device to address different biological processes involved in restenosis and are delivered at different release kinetics matched to the biological process treated. The different agents may also be used to address different diseases from the same drug delivery device. In addition, anti-thrombotic agents may be affixed to at least a portion of the surfaces of the medical device for the prevention of sub-acute thrombosis. To ensure that the different agents remain affixed to the device as well as to each other, masking and de-masking processes may be utilized.06-24-2010
20090043379DRUG DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASES - Provided are drug delivery systems for the prevention and treatment of proliferative diseases, particularly vascular diseases, comprising rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents.02-12-2009
20100222873Self-Buffering Medical Implants - A medical implant includes a bioerodible portion that includes a bioerodible polymer and a bioerodible metal. The bioerodible polymer matrix degrades under physiological conditions to form acidic degradation products. The bioerodible metal degrades under physiological conditions to form basic degradation products. The acidic degradation products and the basic degradation products buffer at least a portion of the medical implant. In one aspect, the bioerodible portion includes a bioerodible polymer matrix and a bioerodible metal within the bioerodible polymer matrix. In another aspect, the medical implant can include a body, a plurality of discrete deposits of the bioerodible polymer on the body, and a plurality of discrete deposits of the bioerodible metal on the body.09-02-2010
20130218264DRUG DELIVERY SYSTEM AND METHOD OF MANUFACTURING THEREOF - A method of modifying the surface of a medical device to release a drug in a controlled way by providing a barrier layer on the surface of one or more drug coatings. The barrier layer consists of modified drug material converted to a barrier layer by irradiation by an accelerated neutral beam derived from an accelerated gas cluster ion beam. Also medical devices formed thereby.08-22-2013
20120245677BIORESORBABLE NITRIC OXIDE AGONIST PRODRUG SCAFFOLDS FOR VASCULAR STENTS - The present invention relates to a bioresorbable scaffold for a vascular stent comprising a nitric oxide agonist and a polymer comprising a lactide, a glycolide and a lactone. The nitric oxide agonist is a statin or a HMG CoA reductase inhibitor. The nitric oxide agonist may be coated on the polymer, incorporated within the polymer or chemically bonded to the polymer. The invention also relates to a method for treating atherothrombosclerotic occlusive disease of an artery comprising implanting into the artery a stent with a bioresorbable scaffold comprising a nitric oxide agonist and a polymer comprising a lactide, a glycolide and a lactone, wherein the nitric oxide agonist is exuded from or released from the bioresorbable scaffold.09-27-2012
20090112310Nanoporous Drug Release Structure for Drug Elute Instruments and the Preparation Method Thereof - The present invention relates to a nanoporous configuration for drug release used in a drug-eluting device and its preparation, employing acid corrosion or anode oxidation to prepare pores, or employing acid corrosion to prepare pores firstly, then employing anode oxidation or micro-arc oxidation combined with micro-arc nitridation to prepare single sized or two sized or multiple sized nanopores, as well as a uniform size distributed or two or more nonuniform size distributed in pore diameter or pore depth h nanopores on the raw material of device body directly. The preparation process includes: {circle around (1)} Pre-treating the surface of the device body, {circle around (2)} Preparing pore, {circle around (3)} Post-treating the surface of the device body, {circle around (4)}preparing drug, {circle around (5)} Spraying drug etc. The nanoporous configuration lowers the risk of forming thrombus after the drug-delivery device with polymer carrier is implanted into the tissue. The device also controls the release rate of drug efficiently and lowers the incidence of restenosis significantly.04-30-2009
20110130829Medical Devices Containing Therapeutic Agents - The present invention pertains to implantable or insertable medical devices which comprise a substrate and one or more therapeutic-agent-containing regions contain one or more therapeutic agents. In various aspects of the invention, one or more characteristics of such therapeutic-agent-containing regions are controlled. Further aspects of the invention relate to methods of forming such devices and to methods of using such devices.06-02-2011
20080275543Stent - In at least one embodiment, the invention is directed to mechanisms that affect the elution rate of a therapeutic agent that has been deposited on the surface of at least a portion of a stent. Mechanisms include grooves formed in the therapeutic agent that is coating at least a portion of the surface of the stent.11-06-2008
20110251677Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings - Provided herein are coating designs for the tailored release of two therapeutic agents from polymer coatings and methods of making and using the same.10-13-2011
20090069883MEDICAL DEVICE WITH SPONGE COATING FOR CONTROLLED DRUG RELEASE - The medical devices of the invention comprise an expandable portion which is covered with a sponge coating for release of at least one biologically active material. The sponge coating is made of a non-hydrogel polymer having a plurality of voids. The device can further include means for infusing or expelling the biologically active material or drug into the voids. The drug is delivered to the body lumen of a patient by expelling the drug and inflating or expanding the expandable portion of the catheter or device.03-12-2009
20110029068DRUG DELIVERY SYSTEM AND METHOD OF MANUFACTURING THEREOF - Irradiation of a surface of a material with a gas cluster ion beam modifies the wettability of the surface. The wettability may be increased or decreased dependent on the characteristics of the gas cluster ion beam. Improvements in wettability of a surface by the invention exceed those obtained by conventional plasma cleaning or etching. The improvements may be applied to surfaces of medical devices, such as vascular stents for example, and may be used to enable better wetting of medical device surfaces with liquid drugs in preparation for adhesion of the drug to the device surfaces. A mask may be used to limit processing to a portion of the surface. Medical devices formed by using the methods of the invention are disclosed.02-03-2011
20100331965COATED DEVICES AND METHOD OF MAKING COATED DEVICES THAT REDUCE SMOOTH MUSCLE CELL PROLIFERATION AND PLATELET ACTIVITY - The present invention relates generally to the maintenance of blow flood using drug eluting stents and/or other coated medical devices to increased length of time of blood flow. Further, the present invention relates to drug-releasing coated devices for reducing smooth muscle cell proliferation and platelet activity to further limit restenosis utilizing resveratrol and quercetin, polyphenols that are linked to the cardioprotection of red wine consumption. The present invention also provides products and methods for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, platelet cell activation and other clotting mechanisms, occlusive disease, or other abnormal lumenal cellular proliferation condition in a location within the body of a patient.12-30-2010
20100241219MEDICAMENT DELIVERY ARTICLE, ACCESSORY & SYSTEM - An adjunctive accessory article (09-23-2010
20100331970Compounds and Methods for the Prevention or Treatment of Restenosis - A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof. A pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof for the prophylaxis or treatment of restenosis. A drug eluting stent, wherein the drug is Annexin A5 or a functional analogue or variant thereof, and a method of making such a stent.12-30-2010
20100331967MEDICATED STENT HAVING MULTI-LAYER POLYMER COATING - This invention relates to stents having medicated multi-layer hybrid polymer coatings, useful for the treatment of stenosed vasculature or other body passages.12-30-2010
20100331966BIOCORRODIBLE IMPLANT HAVING AN ACTIVE COATING - One embodiment of the invention relates to an implant having a basic body composed of a biocorrodible material and having an active coating or filling of a cavity, consisting of or containing the components 12-30-2010
20100228342Laminated Drug-Polymer Coated Stent with Dipped and Cured Layers - The present invention provides a method of applying a drug-polymer coating on a stent. A stent framework is dipped into a first polymeric solution including a first polymer, a first therapeutic agent, and a first solvent. The polymeric solution is dried and the first polymer is cured to form a thin drug-polymer layer on the stent framework. The steps of dipping the stent framework into the first polymeric solution, drying the first polymeric solution, and curing the first polymer are repeated until a target drug-polymer coating thickness is disposed on the stent framework. A drug-polymer coated stent including a stent framework and a laminated drug-polymer coated stent, a system for treating a vascular condition, and a method of treating a vascular condition are also disclosed.09-09-2010
20110009954METHOD FOR MANUFACTURING OF DRUG-RELEASING STENT COATED WITH TITANIUM-OXIDE THIN FILM - Disclosed is a method for manufacturing a drug-releasing stent, including: coating a titanium dioxide or nitrogen-doped titanium dioxide thin film on a metal stent; and attaching a drug on the surface of the titanium oxide thin film. More specifically, the method for manufacturing a drug-releasing stent includes: coating a titanium dioxide or nitrogen-doped titanium dioxide thin film on a metal stent, which can be inserted into the blood vessel, by plasma enhanced chemical vapor deposition (PECVD); modifying the surface of the titanium oxide thin film with hydroxyl groups by low-temperature plasma; and chemically attaching a drug such as an antithrombotic drug or a neointimal hyperplasia inhibitor, so that the drug may be released in the blood vessel in a sustained manner.01-13-2011
20100198343COATING FOR IMPLANTABLE DEVICES AND A METHOD OF FORMING THE SAME - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.08-05-2010
20110046723COATED IMPLANTABLE MEDICAL DEVICE - A coated implantable medical device 02-24-2011
20110034995STENTS WITH DRUG-CONTAINING AMPHIPHILIC POLYMER COATING - It is provided that a vascular stent having an amphiphilic polymer coating is loaded with a restenosis inhibiting agent which is sparingly soluble in water, whereby delayed release of the agent takes place after implantation of the stent.02-10-2011
20110245914STENT HAVING ACTIVE RELEASE RESERVOIRS - Devices for the controlled release of one or more drugs are provided. The devices include an implantable stent, at least two reservoirs in the stent, and a release system contained in each of the at least two reservoirs, wherein the release system comprises one or more drugs for release.10-06-2011
20100152841ADHESION PROMOTING PRIMER FOR COATED SURFACES - An expandable medical device includes a plurality of elongated struts, forming a substantially cylindrical device which is expandable from a first diameter to a second diameter. A plurality of different beneficial agents may be loaded into different openings within the struts for delivery to the tissue. For treatment of conditions such as restenosis, different agents are loaded into different openings in the device to address different biological processes involved in restenosis and are delivered at different release kinetics matched to the biological process treated. The different agents may also be used to address different diseases from the same drug delivery device. In addition, anti-thrombotic agents may be affixed to at least a portion of the surfaces of the medical device for the prevention of sub-acute thrombosis. To ensure that the different agents remain affixed to the device as well as to each other, primer layers may be utilized.06-17-2010
20090062909STENT WITH POLYMER COATING CONTAINING AMORPHOUS RAPAMYCIN - A coated coronary stent, comprising: a stainless steel sent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.03-05-2009
20100137977Coating for Medical Device Having Increased Surface Area - Described herein are implantable medical devices for delivering a therapeutic agent to the body tissue of a patient, and methods for making such medical devices. In particular, the implantable medical devices, such as intravascular stents, have a coating which includes at least one coating composition and has an exposed abluminal surface and an exposed luminal surface or exposed side surface.06-03-2010
20090099651LIPID COATINGS FOR IMPLANTABLE MEDICAL DEVICES - Disclosed herein are medical devices, such as stents, comprising a porous substrate, and a composition coating and/or impregnating the porous substrate where the composition comprises a bioresorbable carrier (e.g., at least one lipid) and at least one pharmaceutically active agent.04-16-2009
20110245915IGF-I FOR MYOCARDIAL REPAIR - Provided herein are methods for treating an individual having (suffering from) an acute myocardial infarction and drug eluting stents useful for treating such individuals. These methods include treating an individual by introducing, such as by surgically inserting, at a site of an acute coronary artery occlusion upstream of the site of acute myocardial infarction, a drug eluting stent (DES) that is capable of eluting from 25 pg to 950 pg of IGF-1 directly into the coronary circulation. The treatment is specifically directed to stimulation of repair or survival of damaged cardiac muscle or left ventricular remodeling.10-06-2011
20090312833IMPLANTABLE DEVICE - The invention relates to an implantable device for local release of at least one drug at a predefined location in a natural cavity having a wall in the body of a mammal, characterized by at least one drug reservoirs, which can be affixed in the cavity, the drug reservoirs and/or a drug outlet being arranged at a distance from the wall, such that the at least one drug is released at a distance from the wall.12-17-2009
20100131050ABSORBABLE STENT HAVING A COATING FOR CONTROLLING DEGRADATION OF THE STENT AND MAINTAINING pH NEUTRALITY - A biocompatible metallic material may be configured into any number of implantable medical devices, including intraluminal stents. The biocompatible metallic material may comprise a magnesium alloy. The magnesium alloy implantable medical device may be designed to degrade over a given period of time. In order to control the degradation time, the device may be coated or otherwise have affixed thereto one or more coatings, one of which comprises a material for controlling the degradation time and maintain a pH neutral environment proximate the device. Additionally, therapeutic agents may be incorporated into one or more of the coatings on the implantable medical device.05-27-2010
20090216320Magnetic Gradient Targeting And Sequestering Of Therapeutic Formulations And Therapeutic Systems Thereof - A therapeutic system and a method that uses stents, and/or other implantable devices (08-27-2009
20090216319MEDICAL IMPLANT HAVING IMPROVED DRUG ELUTING FEATURES - An implantable drainage device for treatment of a stricture of a body vessel is disclosed. The device comprises a drainage tube including an inlet and extending to an outlet to define a drainage lumen formed through the inlet and the outlet. The drainage tube includes a swell layer and a cast layer formed about the swell layer. The swell layer has a first agent dispersed thereabout for regulated drug elution through the cast layer. The cast layer has a second agent disposed thereabout for drug elution therefrom.08-27-2009
20090216318Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy - The invention provides methods for inhibiting cardiomyopathy and for inhibiting cardiac arrhythmia, by administering to an individual in need thereof a cis-epoxyeicosantrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. In some embodiments, the method comprises administering to the individual a nucleic acid encoding an inhibitor of sEH. Cardiomyopathies treatable by the methods of the invention include cardiac hypertrophy and dilated cardiomyopathy.08-27-2009
20090216317Delivery of Highly Lipophilic Agents Via Medical Devices - An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.08-27-2009
20110178592Implantable Tube And Coating Method Thereof - An implantable tube to be implanted in a human body so as to be used as a circulation path, and a coating method thereof are disclosed. The implantable tube is a structure with a lumen coated with a bioactive material containing a material promoting fusing of the structure implanted in the body with ambient tissues. When the structure coated with a bioactive material is implanted in the body, the reaction of fusing the structure with ambient tissues can be promoted to shorten a stabilization period required until dialysis begins. In addition, since a chemical drug, medicament for inducing the generation of a growth factor promoting fusing of the structure with ambient tissues, is used, the structure can be easily coated.07-21-2011
20100057198Abluminal, Multilayer Coating Constructs for Drug-Delivery Stents - Implantable medical devices may include at least one structural element having an abluminal side, luminal side, and sidewalls between the abluminal and luminal sides. The coating may include at least two continuous coating layers. In some embodiments, the luminal side, and all or a majority of the sidewalls are free of at least two of the coating layers.03-04-2010
20100057196VASCULAR GRAFTS WITH MULTIPLE CHANNELS AND METHODS FOR MAKING - A wall, for example the wall of a vascular graft, has multiple channels within it. The channels may be used to hold drugs or reinforcing fibers. The channels may have a predetermined roughness. The channels may be formed by coextrusion using a soluble material, for example, to define the channels and then dissolving them to open the channels in the extrudate.03-04-2010
20110098803Controlled Degradation Of Stents - Stents fabricated from hydrolytically degradable polymers with accelerated degradation rates and methods of fabricating stents with accelerated degradation rates are disclosed.04-28-2011
20120303115EXPANDABLE DEVICES COATED WITH A RAPAMYCIN COMPOSITION - Medical devices may be utilized for local and regional therapeutic agent delivery. These therapeutic agents or compounds may reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including restenosis, vulnerable plaque, and atherosclerosis in type 2 diabetic patients.11-29-2012
20110034993COATED MEDICAL IMPLANTS - Coated medical devices are disclosed. In certain embodiments of the invention, the coating materials include therapeutic agents, polymers, sugars, waxes, or fats. In certain embodiments of the invention, a medical device is coated on at least a portion of its surface with a first coating comprising a therapeutic agent and a wax or fat. The coated medical device may be a stent or catheter.02-10-2011
20110034994STENTS WITH DRUG-CONTAINING AMPHIPHILIC POLYMER COATING - It is provided that a vascular stent having an amphiphilic polymer coating is loaded with a restenosis inhibiting agent which is sparingly soluble in water, whereby delayed release of the agent takes place after implantation of the stent.02-10-2011
20100331969BIOBENEFICIAL COATING COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, an implantable device coated with the composition, and a method of treating a disorder are provided.12-30-2010
20100305688Medical Devices for Localized Drug Delivery - In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent.12-02-2010
20110178593MEDICATION DEPOT FOR MEDICAL IMPLANTS - An agent depot for mechanical connection to a surface of an endovascular implantable body, comprising one or more polymers, one or more bioactive agents, the agent depot being mechanically connectable to the implantable body by a force fit or an adhesive.07-21-2011
20100262228Implantable Medical Devices Having Bioabsorbable Primer Polymer Coatings - The present disclosure generally relates to implantable medical devices having a metallic surface coated with a bioabsorbable primer polymer layer under a bioabsorbable drug polymer layer. Thus, in addition to the degradation of the drug polymer layer, there is degradation of the primer layer. The underlying metallic framework may or may not degrade depending on whether bioabsorbable or biostable metals are chosen.10-14-2010
20100057197MEDICAL DEVICES HAVING INORGANIC COATINGS FOR THERAPEUTIC AGENT DELIVERY - According to an aspect of the invention, medical devices are provided that comprise a substrate, at least one therapeutic agent disposed over or in the substrate, and at least one inorganic layer disposed over the therapeutic agent and the substrate, wherein the inorganic layer is either a porous inorganic layer or is a non-porous layer that becomes a porous inorganic layer in vivo. Other aspects of the invention comprise methods for forming medical devices.03-04-2010
20100036481Cardiovascular Devices and Methods - A material in a flowable state is applied to the interstitial pores of a radially-expandable endovascular tubular braid structure to modify the tubular braid structure for use in the treatment of cardiovascular disease. The material is cured to form a membrane at least within the coated interstitial pores. A cardiovascular device, for use in a vascular lumen within a body for treatment of cardiovascular disease, includes a braided body with electroporation means for helping prevent restenosis in a cardiovascular lumen. A method for treating cardiovascular disease includes placing a radially expandable and collapsible medical device within a cardiovascular passageway, positioning it at a target site, and placing it in a radially expanded state. Restenosis at the target site is inhibited by a chosen one of electroporation and iontophoresis. The medical device is collapsed and is then removed from the passageway.02-11-2010
20080243240Biodegradable Metal Barrier Layer for a Drug-Eluting Stent - An implantable medical device includes a substrate, a drug-impregnated layer deposited over the substrate, and a barrier layer at least partially covering the drug-impregnated layer. The barrier layer may be a biodegradable metal, biodegradable metal oxide, or biodegradable metal alloy, such as, magnesium, a magnesium oxide or a magnesium alloy. The drug-impregnated layer includes a therapeutic substance, such as, antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, fibrinolytic, thrombin inhibitor, antimitotic, antiallergic, and antiproliferative substances.10-02-2008
20090036977DRUG-RELEASING STENT HAVING EXTENSION(S) FOR TREATING LONG LESIONS - This invention generally relates to a system for treating body lumens, comprising stents, such as intravascular stents. More particularly, the invention is directed to stents having extensions attached on the ends thereof. The invention is also directed to methods for making and using such stents.02-05-2009
20080255658Degradation Associated Drug Delivery for Drug Eluting Stent and Medical Device Coatings - A system for treating a vascular condition includes a stent having a biodegradable coating on the stent framework. The coating releases a therapeutically effective amount of therapeutic agent as a function of degradation of the coating. Also provided is a method of treating a vascular condition by placing a stent having a biodegradable coating at a treatment site and delivering a therapeutically effective amount of therapeutic agent at the treatment site as a function of degradation of the coating. Also provided is a method of improving the performance of a medical device by including a biodegradable coating on the surface of the device and releasing a therapeutically effective amount of a therapeutic agent at the treatment site as a function of degradation of the coating.10-16-2008
20110264197COATED MEDICAL DEVICE - A coated medical device (10-27-2011
20110118824Intraluminal Prostheses and Carbon Dioxide-Assisted Methods of Impregnating Same with Pharmacological Agents - Intraluminal prostheses and methods of impregnating same with pharmacological agents for delivery within a body of a subject are provided. An intraluminal prosthesis comprising polymeric material is immersed in a mixture of carrier fluid and pharmacological agent(s). The mixture of carrier fluid and pharmacological agent is pressurized for a time sufficient to cause the polymeric material of the intraluminal prosthesis to swell such that the carrier fluid and pharmacological agent at least partially penetrate the swollen polymeric material. Pressure is then removed such that the carrier fluid diffuses out of the swollen polymeric material and such that a predetermined amount of the pharmacological agent remains elutably trapped within the polymeric material.05-19-2011
20110137407BARE METAL STENT WITH DRUG ELUTING RESERVOIRS - Implantable medical devices may be utilized to locally delivery one or more drugs or therapeutic agents to treat a wide variety of conditions, including the treatment of the biological organism's reaction to the introduction of the implantable medical device. These therapeutic agents may be released under controlled and directional conditions from a stent so that the one or more therapeutic agents reach the correct target area, for example, the surrounding tissue.06-09-2011
20110137406BIOACTIVE STENTS FOR TYPE II DIABETICS AND METHODS FOR USE THEREOF - The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.06-09-2011
20120310329SUSTAINED DRUG-RELEASING STENT - A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.12-06-2012
20090326645Methods Of Application Of Coatings Composed Of Hydrophobic, High Glass Transition Polymers With Tunable Drug Release Rates - The present invention relates to methods of applying a drug—polymer coating layer onto an implantable medical device or another substrate, and the use of a choice of solvents to adjust the release of the drug from the coating. The drug to polymer ratio is about 1:1 to 1:3 on a mass basis. The polymer and the drug are hydrophobic.12-31-2009
20100082095Coatings Including Dexamethasone Derivatives And Analogs And Olimus Drugs - The present invention encompasses a coating on the surface of a substrate and the coated substrates. The coating includes a polymer, an olimus drug (sirolimus, everolimus, zotarolimus, etc.), and a dexamethasone derivative. The polymer may be a hydrophobic polymer, preferably a fluoropolymer, and more preferably a fluoropolymer with at least 25% vinylidene fluoride by weight.04-01-2010
20120150284IMPLANT COMPRISING AN ACTIVE-AGENT-CONTAINING COATING COVERING THE IMPLANT AT LEAST IN SECTIONS - The invention relates to an implant comprising an active-agent-containing coating which covers the implant at least in sections. The coating is composed of at least two subsections; a first subsection contains the at least one active substance, and a second subsection contains an auxiliary agent.06-14-2012
20090292351STENTS HAVING BIOABSORBABLE LAYERS - Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.11-26-2009
20110190875Drug Delivery After Biodegradation Of The Stent Scaffolding - Disclosed herein is a stent comprising: a bioabsorbable polymeric scaffolding; and a coating comprising a bioabsorbable material on at least a portion of the scaffolding, wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating.08-04-2011
20100023116BIOCORRODIBLE IMPLANT WITH A COATING CONTAINING A DRUG ELUTING POLYMER MATRIX - The invention relates to an implant having a base body, consisting completely or partially of a biocorrodible metallic material, such that it decomposes in an aqueous environment to form an alkaline product, and the base body has a coating or a cavity filling, comprising a polymer matrix and at least one drug embedded in the polymer matrix, characterized in that at least one polymer of the matrix and the at least one drug are coordinated so that the drug elution rate from the matrix is increased with an increase in pH.01-28-2010
20100023115DRUG-ELUTING STENT - A stent for delivering therapeutic agents to a body lumen includes a plurality of circumferential serpentine bands with each band comprising a plurality of struts. At least one strut has at least one first well region and at least one second well region. The at least one first well region has a first thickness, the at least one second well region has a second thickness, the first thickness being greater than the second thickness. Each well region defines a well having a depth. At least some of the wells contain a therapeutic agent.01-28-2010
20100016957DEVICE AND METHOD FOR CONTROLLED DELIVERY OF CHEMICAL SUBSTANCES - A medical device for introduction into a body comprises a body-insertable part (01-21-2010
20100016956Triazole compounds and methods of making and using the same - The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. The compounds have the following structure: wherein T is the macrocyclic part.01-21-2010
20100179646GLUCOSE OXIDASE TECHNIQUES - Apparatus and methods are described including an implantable medical device for implanting in contact with a portion of a subject's body. Glucose oxidase, having a mass thereof, is coupled to the medical device. The medical device does not have coupled thereto a mass of glucose that exceeds 0.01 percent of the mass of the glucose oxidase. Other embodiments are also described.07-15-2010
20090030505Drug eluting implantable medical device with hemocompatible and/or prohealing topcoat - The present invention relates to implantable medical devices coated with polymer having hemocompatible and/or prohealing moieties appended thereto and to their use in the treatment of vascular diseases.01-29-2009
20110307053POLYMER METAL AND COMPOSITE IMPLANTABLE MEDICAL DEVICES - A device and a method of manufacturing an implantable medical device, such as a stent, are described herein. The device includes a metallic region composed of a bioerodable metal and a polymer region composed of a biodegradable polymer contacting the metallic region. The metallic region may erode at a different rate when exposed to bodily fluids than the polymer region when exposed to bodily fluids. In certain embodiments, the polymer region is an outer layer and the metallic region is an inner layer of the device.12-15-2011
20090118819Nitric Oxide Coatings for Medical Devices - The disclosure provides for devices and coatings that are substantially free of organic solvent sand suitable for insertion into a patient, and that comprise a metal layer and a coating with a thickness of about 20 nm to about 2000 nm wherein the coating comprises a biocompatible polymer comprising at least one residue covalently bonded to a nitric oxide generating compound.05-07-2009
20110009955COMPOUNDS AND METHOD FOR COATING SURFACES IN A HEMOCOMPATIBLE MANNER - The invention concerns oligosaccharides and polysaccharides as well as the use of these oligosaccharides and/or polysaccharides, which contain the sugar unit N-acylglucosamine or N-acylgalactosamine for the production of hemocompatible surfaces as well as methods for the hemocompatible coating of surfaces with said oligosaccharides and/or polysaccharides, which imitate the common biosynthetic precursor substance of heparin, heparan sulphates and chitosan. The invention further describes methods for producing said oligosaccharides and/or polysaccharides and discloses various possibilities of using hemocompatibly coated surfaces. The invention relates particularly to the use of said oligosaccharides and/or polysaccharides on stents with at least one according to invention deposited hemocompatible coating, which contains an antiproliferative, antiinflammatory and/or antithrombotic active agent, methods for the preparation of said stents as well as the use of said stents for the prevention of restenosis.01-13-2011
20100198344SUSTAINED DRUG-RELEASING STENT - A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.08-05-2010
20120046734MEDICAL DEVICES AND METHODS OF MAKING THE SAME - Medical devices, such as endoprostheses, and related methods are disclosed.02-23-2012
20120004720G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES - This invention provides novel peptides, and other agents, that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.01-05-2012
20120209371DRUG ELUTING IMPLANTABLE MEDICAL DEVICE WITH HEMOCOMPATIBLE AND/OR PROHEALING TOPCOAT - The present invention relates to implantable medical devices coated with polymer having hemocompatible and/or prohealing moieties appended thereto and to their use in the treatment of vascular diseases.08-16-2012
20120209372DRUG ELUTING IMPLANTABLE MEDICAL DEVICE WITH HEMOCOMPATIBLE AND/OR PROHEALING TOPCOAT - The present invention relates to implantable medical devices coated with polymer having hemocompatible and/or prohealing moieties appended thereto and to their use in the treatment of vascular diseases.08-16-2012
20120010698Implantable Pressure-Actuated Drug Delivery Systems and Methods of Manufacture and Use - Implantable pressure-actuated systems to deliver a drug and/or other substance in response to a pressure difference between a system cavity and an exterior environment, and methods of fabrication and use. A pressure-rupturable membrane diaphragm may be tuned to rupture at a desired rupture threshold, rupture site, with a desired rupture pattern, and/or within a desired rupture time. Tuning may include material selection, thickness control, surface patterning, substrate support patterning. The cavity may be pressurized above or evacuated below the rupture threshold, and a diaphragm-protective layer may be provided to prevent premature rupture in an ambient environment and to dissipate within an implant environment. A drug delivery system may be implemented within a stent to release a substance upon a decrease in blood pressure. The cavity may include a thrombolytic drug to or other substance to treat a blood clot.01-12-2012
20110166646Drug Eluting Stent and Method of Making the Same - A drug eluting stent comprising a multilayer tubular structure which includes at least one intermediate layer having reservoirs therein for deposition of a drug, the intermediate layer eluting drug in a lateral direction, and methods of making the same.07-07-2011
20120016467POLYMER-BASED, SUSTAINED RELEASE DRUG DELIVERY SYSTEM - Disclosed is a sustained release system that includes a polymer and a prodrug having a solubility less than about 1 mg/ml dispersed in the polymer. Advantageously, the polymer is permeable to the prodrug and may be non-release rate limiting with respect to the rate of release of the prodrug from the polymer. This permits improved drug delivery within a body in the vicinity of a surgery via sustained release rate kinetics over a prolonged period of time, while not requiring complicated manufacturing processes.01-19-2012
20120016466ABLUMINALLY COATED DRUG-ELUTING STENTS HAVING A FORM-FITTING PROTECTIVE LAYER - A drug-eluting stent, comprising a base body that is made of an implant material, the base body being partially or entirely covered on the abluminal side with an active ingredient-releasing coating that comprises or is made of a polymer and an active ingredient having an antiproliferative effect, characterized in that the stent's luminal surface and the abluminal surface carrying the active ingredient-releasing coating are covered by a biocorrodible protective layer in a form-fitting manner.01-19-2012
20120016465Biodegradable Extravascular Stent - The present invention relates to extravascular supports. In particular, to extravascular supports which are used in vein grafting. More in particular, it relates to extravascular supports which are biodegradable.01-19-2012
20110087321SURFACE-COATED STRUCTURES AND METHODS - The present invention relates to a method for covalently attaching a compound to a stainless steel, tin, iron, or titanium substrate, by contacting exposed surface(s) of the substrate with a synthetic pilin peptide containing a disulfide loop derived from the C-terminal receptor binding protein of Type IV 04-14-2011
20120059455Bioerodible Magnesium Alloy Containing Endoprostheses - A bioerodible endoprosthesis includes a bioerodible magnesium alloy. The bioerodible magnesium alloy includes magnesium, between 7 and 8 weight percent aluminum, between 0.4 and 0.8 weight percent zinc, and between 0.05 and 0.8 weight percent manganese.03-08-2012
20120158126IMPLANT AND METHOD FOR PRODUCING THE SAME - The present invention relates to an implant (06-21-2012
20120071966DRUG-RELEASING STENT WITH CERAMIC-CONTAINING LAYER - A vascular or endoluminal stent is adapted to be implanted in a vessel, duct or tract of a human body to maintain an open lumen. The stent includes a base layer of a biologically compatible metal. An intermediate metal particle layer of substantial greater radiopacity overlies the base layer, with particles bonded to the base layer and to each other to leave interstices therebetween as a repository for retaining and dispensing drugs or other agents for time release therefrom. The particles are composed primarily of a noble metal—. Exposed surfaces of the particle layer are coated with ceramic-like iridium oxide or titanium nitrate, as a biocompatible material to inhibit irritation of tissue at the inner lining of the vessel when the stent is implanted.03-22-2012
20110066227Stent with Dynamic Drug Reservoirs - A stent having one or more beneficial agents which enhance the healing effect of the stent. The agent is positioned within a reservoir. The reservoir dynamically releases the agent when the stent is expanded. The reservoir makes use of various changes in stent shape during expansion to assure proper release of the agent. Agent release can be modulated at various points along the stent and with various rates of release. The reservoirs can also be cooperatively combined with features that enhance stent flexibility, structural integrity, and which prevent recoil.03-17-2011
20110066228CARRIER AND KIT FOR INTRALUMINAL DELIVERY OF ACTIVE PRINCIPLES OR AGENTS - A carrier for delivering at least one active principle at an intraluminal site. The carrier includes a carrier body, such as a stent. The carrier body is provided with one or more reservoirs. The reservoirs contain nanoparticles which convey at least one active principle. The nanoparticles also comprise a substance having characteristics of preferential affinity attraction to a desired region at the intraluminal site. The nanoparticles can migrate toward the preferred region.03-17-2011
20100094407Multiple Bioactive Agent Eluting Stents - The apparatus and methods of the present invention in a broad aspect provide novel multiple bioactive agent eluting stents for treating vascular diseases and conditions. Controlled elution of bioactive agents is achieved by the presence of the bioactive agents themselves. One or more characteristics of the bioactive agents cause variations in elution rates or profiles or the other bioactive agents.04-15-2010
20090132031Stent Having Spiral Channel for Drug Delivery - A drug delivery stent is formed by a metallic or polymeric tubular strut which is shaped into a generally cylindrical configuration, the tubular strut having a central lumen for containing a therapeutic substance or drug therein. The tubular strut has a continuous channel extending from the inside surface of the strut to the outside surface of the strut positioned spirally about or in a corkscrew fashion around a circumference of the tubular strut for delivering the therapeutic substance or drug to a stenotic lesion. The spiral or corkscrew channel width may be varied along the length of the strut to control elution rate and/or flexibility of the stent. The pitch of the spiral or corkscrew channel may also be varied along the length of the strut to control flexibility of the stent. The stent may be carried on a balloon of a balloon catheter to a site of a stenotic lesion where the stent is implanted.05-21-2009
20090132030Method Of Modifying A Metal Substrate To Improve Surface Coverage Of A Coating - This application relates to a method of modifying the surface of a metal substrate to improve the surface coverage of a coating applied to the substrate. The method comprises heating at least the surface of the substrate to a temperature within the range of approximately 175-400° C.; and applying at least one layer of the coating to the substrate. In one particular embodiment the substrate is heated to a temperature within the range of 200-350° C. The low temperature heating enhances the hydrophilicity of the metal substrate while avoiding the disadvantages of high temperature thermal oxidation.05-21-2009
20120130481LOCAL VASCULAR DELIVERY OF ADENOSINE A2A RECEPTOR AGONISTS IN COMBINATION WITH OTHER AGENTS TO REDUCE MYOCARDIAL INJURY - A stent or other implantable medical device for the local delivery of a selective adenosine receptor agonist may be utilized in combination with other therapeutic agents to reduce myocardial injury following an acute myocardial infarction. As soon as possible following an acute myocardial infarction a stent or other suitable device comprising and capable of delivering a selective adenosine receptor agonist is positioned in the blood vessel with the occlusion responsible for causing the infarct. Once in position , the stent or other intraluminal device is deployed to remove the occlusion and reestablish blood flow to the specific area, region or tissue volume of the heart. Over a given period of time the selective adenosine receptor agonist alone or in combination with other therapeutic agents elute from the stent or other device into the downstream coronary blood flow into the hypoxic cardiac tissue for a time sufficient to reduce the level of myocardial injury.05-24-2012
20120130480LOCAL VASCULAR DELIVERY OF ADENOSINE A2A RECEPTOR AGONISTS TO REDUCE MYOCARDIAL INJURY - A stent or other implantable medical device for the local delivery of a selective adenosine receptor agonist may be utilized to reduce myocardial injury following an acute myocardial infarction. As soon as possible following an acute myocardial infarction a stent or other suitable device comprising and capable of delivering a selective adenosine receptor agonist is positioned in the blood vessel with the occlusion responsible for causing the infarct. Once in position , the stent or other intraluminal device is deployed to remove the occlusion and reestablish blood flow to the specific area, region or tissue volume of the heart. Over a given period of time the selective adenosine receptor agonist elutes from the stent or other device into the downstream coronary blood flow into the hypoxic cardiac tissue for a time sufficient to reduce the level of myocardial injury.05-24-2012
20120165923STENT - A stent able to minimize occurrences of strain and stress concentration in a drug coat layer upon expansive deformation of the stent in a radial direction to avoid the possibility of the drug separating from the stent, includes a stent body and a drug coating layer coated on the outside surface of the stent body so that the thickness of the drug coating layer gradually decreases toward a bent portion of the stent.06-28-2012
20120165922METHOD OF MODIFYING A COATING ON A MEDICAL DEVICE - Method of modifying the coating of a surface of a medical device by applying a coating to the surface of the medical device, exposing the medical device to an environmental condition that alters the coating morphology, and drying the coating on the medical device. The disclosed subject matter also provides a coated medical device whose one or more surfaces have been modified by this method.06-28-2012
20120215301BIODEGRADABLE IMPLANTABLE MEDICAL DEVICES FORMED FROM SUPER - PURE MAGNESIUM-BASED MATERIAL - The present invention relates to biodegradable implantable medical device, in particular an endoprosthesis body formed at least partly from a constructional material comprising deformable super-pure magnesium or alloy thereof further comprising one or more super-pure alloying elements. The constructional material has a high formability at room temperature, excellent corrosion stability in vivo, an optimum combination of mechanical properties (strength, plasticity) ideally suited for biodegradable endoprosthesises, particularly stents, as such and for various other technical applications.08-23-2012
20120172976Methods and Devices for Delivering Therapeutic Agents to Target Vessels - The present disclosure pertains to stents having a coating applied thereto, wherein the coating comprises a biocompatible polymer/drug mixture, as well as devices comprising a metallic stent, a biocompatible polymeric carrier and a drug.07-05-2012
20100049309COATED MEDICAL DEVICE - A coated medical device (02-25-2010
20100298928Drug Coated Stents - Provided herein is a coated coronary stent, comprising: a stent framework; heparin molecules attached to the stent framework; and a rapamycin-polymer coating wherein at least part of rapamycin is in crystalline form. In one embodiment, the rapamycin-polymer coating comprises one or more resorbable polymers.11-25-2010
20100042206BIOABSORBABLE COATINGS FOR MEDICAL DEVICES - A medical device that is designed to be introduced into a vascular system of a body.02-18-2010
20100016955Triazole compounds and methods of making and using the same - The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.01-21-2010
20120226347Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease - A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.09-06-2012
20120265295INTRAVASCULAR STENT AND METHOD OF USE - An expandable stent is implanted in a body lumen, such as a coronary artery, peripheral artery, or other body lumen for treating an area of vulnerable plaque. The invention provides for a an intravascular stent having a plurality of cylindrical rings connected by undulating links. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen. A central section is positioned between distal and proximal sections and is aligned with the area of vulnerable plaque to enhance growth of endothelial cells over the fibrous cap of the vulnerable plaque to reinforce the area and reduce the likelihood of rupture.10-18-2012
20120239139MEDICAL IMPLANTS CONTAINING FK506 (TACROLIMUS) METHODS OF MAKING AND METHODS OF USE THEREOF - Implants and methods of making same are provided for treatment or prophylaxis of coronary or peripheral vascular constrictions or vascular occlusions, and particularly, stenoses or restenoses, that comprise FK506 in chemically covalently bound, non-covalently bound or physically immobilized form.09-20-2012
20110046722OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE - The invention provides oxazinyl isoflavonoid compounds and compositions containing same, methods for their preparation and their use as therapeutic agents particularly as cardioprotective, anti-inflammatory, anti-oxidant and chemotherapeutic agents.02-24-2011
20120330405Implantable Medical Devices With A Topcoat Layer Of Phosphoryl Choline For Reduced Thrombosis, And Improved Mechanical Properties - The present invention relates to implantable medical devices coated with phosphoryl choline acrylate polymer topcoat layer and their use in the treatment of vascular diseases.12-27-2012
20120323312STENT FOR ENDOLUMINAL DELIVERY OF ACTIVE PRINCIPLES OR AGENTS - The present invention provides a stent for implantation at a site within a human or animal body comprising: an expandable body having an inner surface and an outer surface; and treatment agents applied to the outer surface of the expandable body, the treatment agents comprising a combination of Paclitaxel and FK506 or their derivatives or analogues.12-20-2012
20120323310GAMMA-TOCOPHEROL THERAPY FOR RESTENOSIS PREVENTION - The present invention is directed to a drug eluting stent system, including: a stent; a tocopherol agent coupled to the stent; wherein the stent is adapted to elute the tocopherol agent into a surrounding lumenal wall tissue when implanted along the lumen within a body of a patient.12-20-2012
20120323311STENTS HAVING CONTROLLED ELUTION - Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.12-20-2012
20110319985METHODS AND APPARATUS FOR LOCALIZED ADMINISTRATION OF INHIBITORY MOIETIES TO A PATIENT - Methods and devices are provided for the localized administration to a patient of moieties effective for inhibiting unwanted cellular growth, including restenosis of an artery treated with a stent implant for blockage of blood flow by an atherosclerotic lesion. After implantation of a medical device capable of moiety-binding, moieties effective at inhibiting unwanted cellular growth are administered locally to a patient. In this manner the deleterious side-effects of systemic administration of moieties are avoided. Upon localized administration, the moieties bind the medical device, rendering the medical device itself capable of inhibiting unwanted cellular growth. According to an embodiment, after implantation of a stent, radioactive moieties specific for receptors immobilized on the stent surface are locally administered using a balloon perfusion catheter. The moieties bind specifically the receptors, becoming immobilized thereto, thereby rendering the stent radioactive and effective for inhibiting restenosis.12-29-2011
20110319984Rejuvenation or preservation of germ cells - Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of germ cells or gametes. Certain embodiments disclosed herein include, but are not limited to, methods of modifying germ cells or gametes, or methods of administering modified germ cells or gametes to at least one biological tissue.12-29-2011
20120290075MODIFICATION OF BIOABSORBABLE STENT TO REDUCE THROMBOGENECITY - Bioabsorbable polymer scaffolds with coatings are disclosed that include immobilized antithrombotic agents on the scaffolds or in or on the coatings. The agents act synergistically with antiproliferative agents released from coatings by providing hemocompatibility during and without interfering with antiproliferative agent release. Methods of modifying scaffolds and coatings with the antithrombotic agents are disclosed.11-15-2012
20120290076DRUG-DELIVERY ENDOVASCULAR STENT AND METHOD FOR TREATING RESTENOSIS - A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments and a liquid-infusible mechanical anchoring layer attached to or formed in outer surface of the filaments. A drug coating in the stent is composed of a substantially polymer-free composition of an anti-restenosis drug, and has a substratum infused in the anchoring layer and a substantially continuous surface stratum of drug that is brought into direct contact with the vessel walls at the vascular site. Thus, the rate of release of the anti-restenosis drug from the surface stratum into said vascular site is determined solely by the composition of said drug coating.11-15-2012
20100198342COATING FOR IMPLANTABLE DEVICES AND A METHOD OF FORMING THE SAME - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.08-05-2010
20100198341COATING FOR IMPLANTABLE DEVICES AND A METHOD OF FORMING THE SAME - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.08-05-2010
20100198340Coating for Implantable Devices and a Method of Forming the Same - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.08-05-2010
20100198339Coating for Implantable Devices and a Method of Forming the Same - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.08-05-2010
20100198338Hydrogen Sulfide Donating Polymers - Described herein are hydrogen sulfide (H08-05-2010
20100168841METAL ALLOYS FOR MEDICAL DEVICES - A medical device that is at least partially formed of a novel metal alloy, which novel metal alloy improves the physical properties of the medical device.07-01-2010
20100168842CORONARY STENT WITH ASYMMETRIC DRUG RELEASING CONTROLLED COATING - A coronary stent is provided with asymmetric drug releasing controlled coating used in interventional therapy of coronary disease, containing a bare stent and a coating consisting of drug and carrier, the coating is coated onto the outer wall surface of the bare stent, and is multi-layered. The drug concentration in the coating increases in sequence from the outer layer to the inner layer. The drugs used in different layers of the coating may be identical or different, and particularly may be one or more selected from taxol, rapamycin, heparin, docetaxel and a combination thereof. The carrier may be a random (lactide-glycolide) copolymer having a molecular weight of 50,000-200,000. The drug-coated stent of the present invention employs highly effective drugs, enabling a thinnest coating and reducing the vascular irritation. The drug release is regulated by altering the coating manner so as to satisfy the clinical requirement for controlled drug release. The employed asymmetric coating promotes regenerative repairing of vascular endothelium. The present invention is a drug-coated coronary stent with reasonable design, with the coating capable of effectively preventing vascular restenosis and reducing occurrence of late thrombosis.07-01-2010
20110160845DRUG DELIVERY SYSTEM AND METHOD OF MANUFACTURING THEREOF - In one embodiment, a drug delivery system and method provide a member including a combination of a drug substance and a polymer or other material, and an encapsulating layer formed in an outer surface of the member by gas cluster ion beam irradiation of the outer surface of the member, which encapsulating layer is adapted to determine one or more characteristics of the drug delivery system.06-30-2011
20130023982STENT - A stent is configured to facilitate directional proliferation of cells on the inner surface of the stent to relatively quickly coat the stent surface with the cells so that the onset of late stent thrombosis or restenosis can be reduced or prevented. The stent includes a cylindrical stent main body having openings at both ends and extending along the longitudinal direction between the openings at both ends. A coating layer is provided on the inner surface of the stent main body and contains a substance having a cell adhesion ability to promote the adhesion of cells. The coating layer is formed by arranging multiple linear coating parts, each extending linearly in a striped manner.01-24-2013
20080243241SHORT TERM SUSTAINED DRUG-DELIVERY SYSTEM FOR IMPLANTABLE MEDICAL DEVICES AND METHOD OF MAKING THE SAME - A short-term sustained drug eluting coating for implantable medical devices is disclosed. The coating comprises a biocompatible matrix and at least one pharmacologically or biologically active agent and releases substantially one of all of its payloads within four to six weeks post-implantation. When a combination of pharmacological agents are incorporated in the disclosed sustained drug eluting matrix of a drug/device combination, at least one agent is preferred to substantially release in a short duration. Medical devices benefiting from such a desired sustained drug eluting coating include drug eluting cardiovascular, peripheral, and neurovascular stents, abdominal aortic aneurysm (AAA) prosthesis, anastomosis shunt, arterial/venous (AV) shunts etc. One embodiment of the invention is a sustained release coating or depot on or in a stent that releases substantially all of it payload for ischemic myocardial injury after a heart attack. The coating may be formed from biocompatible stable and absorbable polymers of natural and synthetic origins. Useful pharmacological agents for inhibiting vascular neointimal growth post-angioplasty that leads to restenosis include macrolide polyenes such as a rapamycin and all its derivatives and analogs; paclitaxel and all derivatives and analogs. Useful agents for other vascular conditions such as vulnerable plaques may comprise anti-inflammatory, anti-proliferative agents, and matrix metalloprotease (MMP) inhibitors.10-02-2008
20080234810Amorphous Glass-Coated Drug Delivery Medical Device - An implantable medical device that can include an amorphous glass primer layer, an amorphous glass drug-containing layer and a nanoporous amorphous glass top-coat layer is disclosed.09-25-2008
20080234808Releasable Polymer on Drug Elution Stent and Method - A method for treating a vascular condition is disclosed, the method comprising delivering a stent to a target region of a vessel, the stent including a drug polymer coating including an elution portion and a remaining portion, eluting the elution portion from the delivered stent for an elution period, heating the delivered stent after the elution period; and removing the remaining portion based on the heating.09-25-2008
20120253456METHOD FOR PREPARATION OF ARTIFICIAL BLOOD VESSEL USING TUBE-TYPE POROUS BIODEGRADABLE SCAFFOLD HAVING A DOUBLE-LAYERED STRUCTURE AND STEM CELL, AND ARTIFICIAL BLOOD VESSEL MADE BY THE SAME - The present invention relates to a method for preparation of an artificial blood vessel using a tube-type porous biodegradable scaffold having a double layered structure and a stem cell, and an artificial blood vessel made by the same. Specifically, the present invention relates to a method for preparation of an artificial blood vessel by separately seeding a stem cell onto the inner membrane and an outer membrane of a tube-type porous biodegradable scaffold having a double layered structure, wherein the inner membrane and the outer membrane having different biodegradable polymer nano-fiber arrangements are continuously linked, and by inducing differentiation; and an artificial blood vessel made by the same.10-04-2012
20080215137THERAPEUTIC DRIVING LAYER FOR A MEDICAL DEVICE - The present invention regards the delivery of therapeutic at a target site. Systems that employ the present invention may employ a medical device sized to be inserted into a target site, a driving layer covering at least a portion of an accessible surface of the medical device, and a therapeutic interfaced with at least a portion of the driving layer. In this system, the driving layer may have a material characteristic that serves to release the therapeutic from the medical device when the medical device is at the target site. Other systems that employ the invention may also have properties that include having a driving layer with a higher solubility than the therapeutic at the target site, a medical device that is hydrophobic while the therapeutic is hydrophilic, and a coating covering at least a portion of the therapeutic.09-04-2008
20110313514Drug-eluting stent - A drug-eluting stent comprises a coated layer prepared of a composition comprising a polymer and a drug, the coated layer being a single coated layer with the composition, or comprises a first coated layer prepared of the above composition and a second coated layer with a polymer alone, the first coated layer being coated by the second coated layer. The drug is a vascular intimal hyperplasia inhibitor which does not inhibit proliferation of endothelial cells, and the composition substantially excludes a lipid-soluble low-molecular compound. The polymer in the first layer is a copolymer of lactic acid (monomer A) and a terminal hydroxy straight alkyl carboxylic acid having 3 to 8 carbon atoms, and, if the second coated layer is formed, the polymer in the second coated layer is a poly(lactic acid), a poly(glycolic acid), or a poly(lactic acid-co-glycolic acid).12-22-2011
20100286763DRUG-RELEASING STENT WITH CERAMIC-CONTAINING LAYER - A vascular or endoluminal stent is adapted to be implanted in a vessel, duct or tract of a human body to maintain an open lumen. The stent includes a base layer of a biologically compatible metal. An intermediate metal particle layer of substantial greater radiopacity overlies the base layer, with particles bonded to the base layer and to each other to leave interstices therebetween as a repository for retaining and dispensing drugs or other agents for time release therefrom. The particles are composed primarily of a noble metal. Exposed surfaces of the particle layer are coated with ceramic-like iridium oxide or titanium nitrate, as a biocompatible material to inhibit irritation of tissue at the inner lining of the vessel when the stent is implanted.11-11-2010
20100286762Compositions and Methods for Ameliorating Clinical Electrical Disturbances - Disclosed are compositions and methods for the use of ACT1 peptide or other approaches to targeting the ZO-1 PDZ2 domain to treat non-injury related disturbance to electrical activation and ion transients in organ systems.11-11-2010
20120029626DRUG DELIVERY ENDOVASCULAR STENT AND METHOD OF USE - A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments where at least one surface of the filaments has a roughened or abraded surface. The stent may include a therapeutic agent on the abraded surface.02-02-2012

Patent applications in class Drug delivery

Patent applications in all subclasses Drug delivery